The ubiquitin proteasome system contains a plethora of novel therapeutic targets. Progenra's ability to discover novel structures employing its high throughput assays has created several opportunities for establishing partnerships with other companies.


Progenra is pleased to collaborate with Ono Pharmaceuticals.

Ono logo-24657



Academic Partners

Recognizing that: 1) there is still much to discover in the ubiquitin-proteasome system; and 2) there is a need for rigorous validation of ubiquitin proteasome system targets, Progenra encourages academic laboratories to contact us with potential collaborative projects. Progenra is especially interested in prospective collaborations with translational potential.

We are pleased to have collaborations with several leading national and international academic institutions.

Baylor College of Medicine Tokyo University
Brigham & Women's Hospital Trinity College Dublin
Children's Hospital of Philadelphia University of Alabama at Birmingham
Chinese Academy of Sciences University of Alberta
Harvard University Dana-Farber Cancer Institute University of California, San Diego
Emory University University of California, Los Angeles
Curie Institute Paris University of Glasgow
Johns Hopkins University School of Medicine University of Illinois Chicago`
Karolinska Institute University of Iowa
Kumamoto University University of Michigan Medical Center
Louisiana State University University of Oxford
Mayo Clinic University of Pennsylvania School of Medicine
Massachusetts General Hospital University of Pittsburgh
Northwestern University University of Queensland
Purdue University University of Toronto
Scripps Institute Virginia Tech